Patel S, et al. - In previously-treated patients with liposarcoma/leiomyosarcoma (LPS/LMS), researchers tested trabectedin vs dacarbazine in this randomized phase 3 study. Using randomization 2:1, they assigned 384 patients to receive trabectedin and 193 patients to receive dacarbazine, via intravenous route, every 3 weeks. Overall survival (OS) was the primary objective. Progression-free survival, objective response rate, safety, and patient-reported outcomes were secondary objectives, all earlier reported and showing superior disease control with trabectedin. Between LPS/LMS patients taking trabectedin or dacarbazine, comparable survival was shown by the final OS results, this finding was consistent with the interim analysis results. With trabectedin, improved disease control was shown by both LPS and LMS.